Remarkable: Pembrolizumab (Keytruda) now also for advanced non-small cell lung cancer (NSCLC)

Last Updated on

October 06, 2015 –  Lung cancer is the leading cause of cancer death in the United States, with an estimated 221,200 new diagnoses and 158,040 deaths in 2015, according to the National Cancer Institute. Among lung cancers, non-small cell lung cancer (NSCLC) is the most common type of lung cancer.

Very recently, the American Food and Drug Administration (FDA) granted accelerated approval for Prembrolizumab (Keytruda) to treat patients with advanced (metastatic) non-small cell lung cancer (NSCLC) whose disease has progressed after other treatments and with tumors that express a protein called PD-L1 which is encoded by the CD274 gene in humans. In this case, Prembolizumab (Keytruda) was approved for use with a companion diagnostic, the PD-L1 IHC 22C3 pharmDx test, the first test designed to detect PD-L1 expression in non-small cell lung tumors.

This is remarkable in two ways. On one hand, in 2014, Prembolizumab (Keytruda) was already approved to treat patients with advanced melanoma following treatment with ipilimumab, a type of immunotherapy. With the present approval of Prembolizumab (Keytruda) it seems that one molecular target, PD-L1 in this case, may play a role in different types of cancers, and therefore make one single drug useful in the therapy of a number of cancer-related indications. On the other hand, Prembolizumab (Keytruda) was approved for treatment of NSCLC to be used together with the the PD-L1 IHC 22C3 pharmDx test: In other words, physicians are able to target their therapy towards patients whose tumors express PD-L1 and are therefore particularly amenable to the therapeutic effects of Prembolizumab (Keytruda).

Prembolizumab (Keytruda) works by targeting the cellular pathway known as PD-1/PD-L1 (proteins found on the body’s immune cells and some cancer cells). By blocking this pathway, Prembolizumab (Keytruda) may help the body’s immune system fight the cancer cells. Another drug, Nivolumab (Opdivo), also targets the PD-1/PD-L1 pathway and was approved to treat squamous non-small cell lung cancer (a certain kind of NSCLC) in 2015.

The effectiveness of Prembolizumab (Keytruda) in NSCLC was demonstrated in a subgroup of 61 patients enrolled within a larger multicenter, open-label, multi-part study. The subgroup consisted of patients with advanced NSCLC that progressed following platinum-based chemotherapy or, if appropriate, targeted therapy for certain genetic mutations (ALK or EGFR). This subgroup also had PD-L1 positive tumors based on the results of the 22C3 pharmDx diagnostic test. Study participants received 10 mg/kg of Keytruda every two or three weeks. The major outcome measure was overall response rate (percentage of patients who experienced complete and partial shrinkage of their tumors). Tumors shrank in 41 percent of patients treated with Keytruda and the effect lasted between 2.1 and 9.1 months.

The flip-side of the coin is that Prembolizumab (Keytruda) comes with a rather complicated and serious profile of adverse effects. Thus, according to FDA, the safety of Prembolizumab (Keytruda) was studied in 550 patients with advanced NSCLC. The most common side effects of Prembolizumab (Keytruda) included fatigue, decreased appetite, shortness of breath or impaired breathing (dyspnea) and cough. However, Prembolizumab (Keytruda) also has the potential to cause severe side effects that result from the immune system effect of Prembolizumab (Keytruda) (known as “immune-mediated side effects”). In the 550 study participants with advanced NSCLC, severe immune-mediated side effects occurred involving the lungs, colon and hormone-producing glands. Other uncommon immune-mediated side effects were rash and inflammation of blood vessels (vasculitis). Women who are pregnant or breastfeeding should not take Keytruda because it may cause harm to a developing fetus or newborn baby. Across clinical studies, a disorder in which the body’s immune system attacks part of the peripheral nervous system (Guillain-Barre Syndrome) also occurred.

Tags: , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Leave a Reply

Optional: Social Subscribe/Login

Notify of
Joseph Gut

We just heard about Mr. Jimmy Carters progress on Keytruda from The Carter Center. Read on here: This is the according note on Facebook: “The Carter Center UPDATE FROM THE CARTER CENTER ON PRESIDENT CARTER’S HEALTH ATLANTA—President Carter has received good news from his Winship Cancer Institute doctors. They tell him that recent tests have shown there is no evidence of new malignancy, and his original problem is responding well to treatment. Further tests will continue.” The Carter Center 10 hrs · Atlanta, GA, United States · . UPDATE FROM THE CARTER CENTER ON PRESIDENT CARTER’S HEALTH ATLANTA—President Carter… Read more »


[…] week for treating NSCLC specifically for patients whose tumors expressed PD-L1. Thasso Post had a recent report on Pembrolizumab […]

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • Genes, the social environment, and adolescent smoking September 17, 2019
    Adolescence is a time of dramatic change. It marks a period of significant physical transformation—such as the drive toward sexual maturity. But it can also be a time of considerable psychological change and social experimentation.
  • Cause of rare, fatal disorder in young children pinpointed September 17, 2019
    Scientists at Washington University School of Medicine in St. Louis appear to have solved a decades-long mystery regarding the precise biochemical pathway leading to a fatal genetic disorder in children that results in seizures, developmental regression and death, usually around age 3. Studying a mouse model with the same human illness—called Krabbe disease—the researchers also […]
  • Gene-targeted cancer drugs, slow release overcome resistance September 16, 2019
    Biomedical engineers at Duke University have developed a method to address failures in a promising anti-cancer drug, bringing together tools from genome engineering, protein engineering and biomaterials science to improve the efficacy, accuracy and longevity of certain cancer therapies.
  • Genetic mutation appears to protect some people from deadly MRSA September 16, 2019
    An inherited genetic tendency appears to increase the likelihood that a person can successfully fight off antibiotic-resistant staph infections, according to a study led by Duke Health researchers.
  • Renegade genes caught red handed September 16, 2019
    The guardians of the human genome that work to prevent potentially disease-causing gene expression might not be as effective at their jobs as previously thought, according to new University of Arizona research.